ClinicalTrials.Veeva

Menu

Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease

Pfizer logo

Pfizer

Status and phase

Completed
Phase 1

Conditions

Parkinson's Disease

Treatments

Drug: PF-06412562
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT02006290
B7441003

Details and patient eligibility

About

The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be evaluated.

Enrollment

19 patients

Sex

All

Ages

30 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female subjects with a diagnosis of idiopathic Parkinson's disease.
  • Daily L-dopa dose between 300 and 1200 mg.
  • MBRS score >1.

Exclusion criteria

  • Surgical intervention for Parkinson's disease.
  • History of troublesome dyskinesias.
  • Any significant AXIS I psychiatric disease.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

19 participants in 2 patient groups, including a placebo group

1
Experimental group
Treatment:
Drug: PF-06412562
2
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems